巨和粒治疗恶性肿瘤化疗后血小板减少的临床研究

目的观察巨和粒(rhIL-11)治疗恶性肿瘤患者化疗所致血小板减少的临床疗效与毒副作用。方法采取自身对照,即恶性肿瘤患者化疗后血小板减少至50×109/L以下20例,定期复查血常规使之自然恢复≥80×109/L,作为自身对照(第一周期),在下一疗程化疗结束后24h给予巨和粒25μg/kg-1·d-1皮下注射,连用4～14d(平均8d),观察15d(第二周期)。同一患者前后化疗方案及剂量强度相同。结果第二周期(化疗+rhIL-11)血小板上升幅度明显高于第一周期,分别为(86.25±31.27)×109/L和(26.91±10.42)×109/L,差异有显著性(P<0.05)。不良反应主要为乏力、肌肉关节疼痛、头痛头晕等,以Ⅰ～Ⅱ度为主。结论巨和粒对恶性肿瘤化疗所致的血小板减少有确切的治疗作用,而且毒副作用少,耐受性好。

Objective To observe the efficacy and the side effects of rhIL - 11（juheli） on malignant tumor patients with thrombocytopenia induced by chemotheraphy. Method The test adopted own control, Twenty patients with chemotherapy - induced thrombocytopenia （plate - reduced to 50 × 10^9/L or lower） received rhIL- 11 at the does of 25 μg/kg^-1 ·d^-1 subcutaneously for average g days after the second cycle of chemotherapy was finished ; the first cycle , when the blood plate improved naturally to 80 × 10^9/L or above , was used as control . The chemotherapy regimen and treatment intensity remained unchanged in the same patients. Results It was found that the blood plate rose with significantly higher pace in the treatment group than that in the control group （ P 〈 0.05 ）. Major side effect included debilitation, muscle and joint pain and headache et al. Conchlsions The juheli could elevate thrombocytopenia induced by chemotheraphy in malignant tumor patients with slight side-effects with good tolerance .